The London and Cambridge Life Sciences team advised MiroBio on its $97 million series B financing round. The round was led by Medicxi with participation from new investors, OrbiMed and Monograph and existing Series A investors, Oxford Science Enterprises, Samsara BioCapital, SR One and Advent Life Sciences.
MiroBio is a leader in the development of checkpoint agonists to treat autoimmune diseases. Funds will primarily be used to advance MiroBio’s two lead antibody candidates into clinical trials and obtain safety and efficacy data in patients with autoimmune diseases.
The Goodwin team was led by Elizabeth Rhodes with support from and Duy Le.
For more information, please see here.